Trial Profile
An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Adverse reactions
- Sponsors Takeda
- 23 Dec 2021 Results assessing efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children published in the Medicine
- 19 Dec 2018 Status changed from active, no longer recruiting to completed.
- 11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 31 Dec 2018.